The biotech sector is having another one of its moments—the kind that sends retail investors scrambling for the sidelines while long-term money quietly loads up. Macro uncertainty is slamming equities broadly, and a famously high-beta corner of the market like biotech is absorbing more than its fair share of indiscriminate selling.
But history suggests that when the tape gets this ugly, the disconnect between a company’s underlying pipeline value and its stock price can widen into opportunity. “If you’re waiting for the all-clear signal in biotech, you’ll never buy,” notes one veteran healthcare fund manager. “You buy when the narrative is broken but the science isn’t.”
Two names in particular—Moderna (MRNA) and Regeneron (REGN) —are surfacing on value screens as companies whose long-term technology arcs appear increasingly misaligned with their current depressed multiples.
Regeneron has built what amounts to a cash-flow fortress in an industry that often burns billions before seeing a dime. Dupixent, the blockbuster immunology drug co-marketed with Sanofi, continues to print money. The recent label expansion into chronic obstructive pulmonary disease (COPD)—a massive, underserved population—adds fresh legs to a franchise that Wall Street had already pegged for peak sales north of €20 billion. Meanwhile, the high-dose formulation of Eylea (Eylea HD) is doing exactly what it was designed to do: converting patients from the legacy version with a more convenient dosing schedule, largely neutralizing the biosimilar threat.
That steady stream of free cash flow underwrites two things investors crave in a jittery tape: a quarterly dividend and an aggressive share repurchase program.
But the real intrigue lies in Regeneron’s unorthodox approach to the obesity gold rush. While the rest of Big Pharma piles into GLP-1 agonists, Regeneron is quietly developing a muscle-preservation therapy intended as a companion drug. The logic is simple and clinically savvy: patients on weight-loss drugs often shed muscle along with fat. A therapy that mitigates that side effect could become indispensable adjunct therapy. It’s a classic Regeneron move—find the unmet need hiding in plain sight within a blockbuster category.
“If they crack the muscle-wasting problem, they don’t need the best GLP-1,” a biotech analyst at a major investment bank recently wrote. “They own the ecosystem around it.”
Calling Moderna a one-trick pandemic pony is getting increasingly difficult to justify. Yes, the COVID vaccine revenue cliff was steep and painful. But viewing the company through that narrow lens ignores the foundational nature of its mRNA platform.
The technology’s defining advantage is speed. When the next novel pathogen emerges—and it will—Moderna’s ability to design and deploy a vaccine candidate in weeks rather than months or years is a strategic asset that doesn’t show up in a discounted cash flow model. In the near term, that platform is being stress-tested against norovirus, a ubiquitous bug with zero approved vaccines and a clear public health need. Phase 3 data is pending, and the market opportunity is effectively a greenfield.
Further out, mRNA-4157 represents the real re-rating catalyst. This personalized cancer vaccine, in combination with Merck’s Keytruda, delivered a statistically significant reduction in recurrence risk in adjuvant melanoma trials. The program is now in multiple Phase 3 studies. Success in oncology would do more than just add a new product line; it would validate mRNA as a therapeutic modality, forcing the Street to value Moderna less like a vaccine manufacturer and more like a platform company.
At current levels, investors are paying a fraction of the price they were two years ago for a pipeline that is demonstrably more advanced and diversified.
Volatility is the price of admission to biotech’s long-term returns. Regeneron offers the relative safety of a diversified pharma giant with a differentiated growth angle in obesity. Moderna offers a leveraged bet on a platform technology that is just beginning to prove its versatility. Neither stock is likely to bottom on any predictable schedule, but for investors with a multi-year horizon and the patience to look through the noise, the current dislocation looks increasingly like a gift.
